Stella Pharma Corporation
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥229M | ¥269M | ¥961M | ¥323M |
| Gross Profit | ¥207M | ¥217M | ¥846M | ¥279M |
| Operating Income | -¥807M | -¥760M | -¥90M | -¥749M |
| Pretax Income | -¥773M | -¥759M | -¥134M | -¥771M |
| Net Income | -¥779M | -¥764M | -¥141M | -¥781M |
| EPS | -¥26.97 | -¥24.66 | -¥4.22 | -¥22.95 |
| Operating Margin | -352.20% | -282.12% | -9.39% | -231.60% |
| Balance Sheet | ||||
| Total Assets | ¥4,329M | ¥3,821M | ¥5,417M | ¥4,487M |
| Total Equity | ¥2,753M | ¥2,377M | ¥3,207M | ¥2,427M |
| Total Liabilities | ¥1,577M | ¥1,444M | ¥2,210M | ¥2,060M |
| Cash | ¥2,710M | ¥2,053M | ¥3,206M | ¥2,823M |
| Interest-bearing Debt | ¥1,093M | ¥933M | ¥767M | ¥747M |
| Equity Ratio | 63.58% | 62.22% | 59.21% | 54.08% |
| D/E Ratio | 0.40 | 0.39 | 0.24 | 0.31 |
| Cash Flow | ||||
| Operating CF | -¥828M | -¥877M | ¥140M | -¥335M |
| Investing CF | -¥30M | -¥9M | ¥288M | -¥16M |
| Financing CF | ¥292M | ¥228M | ¥721M | -¥33M |
| Free CF | -¥857M | -¥888M | ¥128M | -¥346M |
| Efficiency | ||||
| ROE | -28.30% | -32.13% | -4.39% | -32.18% |
| ROA | -17.99% | -19.99% | -2.60% | -17.41% |
Latest IR Information
-
Contract signing for development and sales partnership with CBSH and Pengbo for expansion into the Mainland China market
To expand BNCT in Mainland China, a development and sales partnership agreement was signed with CBSH and Pengbo. Aims to obtain Chinese approvals and establish a sales framework, anticipating mid-term business expansion.
Read more -
Progress of Research and Development toward expanding BNCT indications in Deep-seated Cancer areas through collaboration with Fujita Medical University
Reporting progress of R&D aimed at expanding BNCT indications into deep-seated cancer areas in collaboration with Fujita Medical University and others. Conducted exploratory research using 18F-FBPA PET, laying the groundwork for expanding indications to deep-seated tumors. Positioned as a pillar...
Read more -
Notice of receipt of partial approval changes for addition of a manufacturing site to ensure stable supply of Stavaronin®
To rebuild a stable supply framework for the BNCT therapeutic Stavaronin®, PMDA submission and receipt of a partial approval change to add a new contract manufacturing site as a manufacturing facility. Approval is expected around January 2027.
Read more -
[Starforma] Basic Agreement on New Particle Beam Therapy｜July 2026
Starforma has entered into a basic agreement with QST Hospital for the development of new particle beam therapy technologies. The company is exploring a new cancer treatment that combines boron pharmaceuticals and particle beams, with minimal impact expected on the...
Read more -
Confirmed Research Framework for New Treatment Concept 'B-NIT'｜July 2026
Our company has collaborated with Okayama University to establish the research framework for a Phase I clinical trial of the B-NIT therapy and has signed an outsourced development contract. We are preparing for physician-led clinical trials, and it is expected...
Read more
Latest News (5 items)
Company Information
About
Stella Pharma Corporation engages in research and development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its products include SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma, meningioma, malignant melanoma and angiosarcoma, glioblastoma, and thoracic malignant tumor. Stella Pharma Corporation was incorporated in 2007 and is headquartered in Osaka, Japan.
